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Repetitive transcranial magnetic stimulation (rTMS) can improve upper limb hemiparesis
after stroke but the mechanism underlying its efficacy remains elusive. rTMS seems to alter
brain-derived neurotrophic factor (BDNF) and such effect is influenced by BDNF gene
polymorphism.
Objectives
To investigate the molecular effects of rTMS on serum levels of BDNF, its precursor
proBDNF and matrix metalloproteinase-9 (MMP-9) in poststroke patients with upper limb
hemiparesis.
Methods
Poststroke patients with upper limb hemiparesis were studied. Sixty-two patients underwent
rehabilitation plus rTMS combination therapy and 33 patients underwent rehabilitation
monotherapy without rTMS for 14 days at our hospital. One Hz rTMS was applied over the
motor representation of the first dorsal interosseous muscle on the non-lesional hemi-
sphere. Fugl-Meyer Assessment and Wolf Motor Function (WMFT) were used to evaluate
motor function on the affected upper limb before and after intervention. Blood samples were
collected for analysis of BDNF polymorphism and measurement of BDNF, proBDNF and
MMP-9 levels.
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Results
Two-week combination therapy increased BDNF and MMP-9 serum levels, but not serum
proBDNF. Serum BDNF and MMP-9 levels did not correlate with motor function improve-
ment, though baseline serum proBDNF levels correlated negatively and significantly with
improvement in WMFT (ρ = -0.422, p = 0.002). The outcome of rTMS therapy was not
altered by BDNF gene polymorphism.
Conclusions
The combination therapy of rehabilitation plus low-frequency rTMS seems to improve motor
function in the affected limb, by activating BDNF processing. BDNF and its precursor
proBDNF could be potentially suitable biomarkers for poststroke motor recovery.
Introduction
Stroke is the leading cause of death and the main cause of long-term disability worldwide.
Hemiparesis is a common disability in patients with stroke. Previous studies indicated that
repetitive transcranial magnetic stimulation (rTMS) can improve poststroke hemiparesis [1,2].
Although rTMS is considered to modulate neuronal plasticity by stimulating cortical excitabil-
ity, the precise mechanism underlying the beneficial effects of rTMS remains obscure [2,3].
Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal plasticity
and in the pathophysiology of various brain disorders [4–9]. Accumulating evidence suggests
that BDNF mediates, at least in part, the therapeutic benefits of rTMS. It is reported that rTMS
increases blood BDNF (mature BDNF + proBDNF) levels in patients with depression [10,11].
Furthermore, daily 5-Hz rTMS for 5 days significantly increased serum levels of BDNF (mature
BDNF + proBDNF) in healthy human subjects, resulting in activation of BDNF-TrkB signaling
[12]. Moreover, val66met polymorphism of the BDNF gene negatively influences the effect of
rTMS on poststroke upper limb hemiparesis [13]. These findings suggest that the observed
changes in peripheral blood are due to rTMS-induced modulation of BDNF-TrkB signaling in
the brain [12].
ProBDNF, the precursor protein of the mature form BDNF, is converted to BDNF by extra-
cellular proteases, such as matrix metalloproteinase-9 (MMP-9). In this regard, the mature
BDNF and proBDNF play important physiological functions by eliciting opposite effects via
TrkB and p75NTR, respectively [7,8,14]. Mature BDNF could be involved in increased brain
excitability, while proBDNF seems to play a role in reducing brain excitability [14]. Consider-
ing the high levels of both proBDNF and mature BDNF in the human serum [15] and their
putative opposing functions, it is clinically and scientifically interesting to measure the individ-
ual serum levels of mature BDNF and proBDNF in human subjects [7,8,16–18]. One previous
study indicated that serum levels of mature BDNF, but not proBDNF, were significantly lower
in patients with depression than those of healthy control subjects [19]. The same study also
showed significant correlations between serumMMP-9 levels and the severity of depression,
quality of life, and social function scores in depressed patients [19]. To our knowledge, how-
ever, there were no studies that assessed serum levels of mature BDNF, proBDNF, and MMP-9
in stroke patients before and after rTMS.
The present study was designed to determine the molecular effects of rTMS on serum levels
of mature BDNF, proBDNF and MMP-9 in poststroke patients with upper limb hemiparesis,
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and the relationship between serum biomarkers and functional evaluation of upper limb hemi-
paresis in patients after stroke.
Materials and Methods
Subjects
The study subjects were inpatients admitted to Tokyo General Hospital for rehabilitation ther-
apy for hemiparesis after stroke during the period between February 2012 and March 2014.
The inclusion criteria were: 1) Age at intervention of 30–90 years. 2) Time after onset of stroke
>1 month. 3) Mild or moderate upper limb hemiparesis (able to flex fingers of the affected
upper limb). 4) At a probable plateau state with regard to recovery of upper limb hemiparesis
as determined by serial evaluation after the onset of stroke [no increase in the Fugl–Meyer
Assessment (FMA) score during the latest two-weeks]. 5) No cognitive deficits (Mini Mental
State Examination (MMSE)>23 and if with aphasia, Raven’s Colored Progressive Matrices
(RCPM)> average score for the same age—2SD). 6) No history of convulsions. 7) No intracra-
nial metal or cardiac pacemaker. The exclusion criteria were: 1) Unacceptable quality of blood
samples collected from the patients (hemolysis, insufficient volume and melting of frozen sam-
ples), and 2) missing values of clinical evaluation before and/or after intervention.
The study was approved by the ethics committees of The Jikei University School of Medi-
cine and Tokyo General Hospital and the Biomedical Research Ethics Committee of the Grad-
uate School of Medicine at Chiba University. A signed informed consent about participation in
this study and rTMS treatment was obtained from each patient.
Application of rTMS
Low-frequency rTMS inhibits cortical excitability in the stimulated region [20], whereas high-
frequency rTMS facilitates cortical excitability [21]. Based on these properties, many studies
have reported that low-frequency rTMS should be applied over the primary motor area of the
non-lesional hemisphere while high-frequency rTMS should be applied over the primary
motor area of the lesional hemisphere in order to improve poststroke upper limb hemiparesis
[1]. This is because enhancement of cortical excitability of the lesional hemisphere facilitates
motor recovery in stroke patients [22] and the direct effect of high-frequency rTMS or the indi-
rect effect of low-frequency rTMS through a reduction of interhemispheric inhibition towards
the lesional hemisphere from the non-lesional hemisphere is expected.
Low-frequency rTMS was used in the present study. For this purpose, a 70-mm figure-8 coil
andMagPro R30 stimulator (MagVenture Company, Farum, Denmark) were used for applica-
tion of rTMS. According to the safety recommendations and hospital protocol [1, 23], we applied
1-Hz rTMS over the motor area that represents the first dorsal interosseous (FDI) muscle on the
nonlesional hemisphere. The optimal site of stimulation was defined as the location where the
largest motor evoked potentials (MEPs) in the FDI muscle of the unaffected upper limb were elic-
ited on electromyography. The motor threshold (MT) of the FDI muscle of the unaffected upper
limb was defined as the lowest intensity of stimulation that could activate MEPs of the FDI mus-
cle. The intensity of stimulation was subsequently set at 90% of the measured MT of the FDI
muscle. Each session consisted of 1200 pulses and two sessions were conducted per day. Each
patient underwent a total 22 treatment sessions delivered on a daily basis except for holidays.
Rehabilitation therapy
In both groups, patients received rehabilitation comprising 60-min training in the morning
and 60-min training in the afternoon, provided by a physiotherapist, every day over a period of
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two weeks. Rehabilitation mainly consisted of shaping techniques and repetitive task practice
designed to use intensively the affected upper limb. The shaping techniques included reaching
forward to move a cup from one place to another, wiping the surface of the table with a towel,
picking up a hairbrush and combing hair, writing letters with a pencil, drawing pictures with a
pen, handling chopsticks to pick up small objects, folding an umbrella and other activities
based on activity of daily living. The repetitive task practice typically included turning over
cards, squeezing clay, gripping a small ball, and pinching small coins. Although each 60-min
training time usually included 30 minutes of shaping techniques and 30 minutes of repetitive
task practice, the proportion of training time was modified depending on improvement in
motor function of the affected upper limb, if necessary. In patients who received rTMS, each
60-min training was scheduled to start soon after the application of rTMS.
Clinical evaluation
The MMSE was evaluated before the treatment. RCPM was used instead of MMSE in patients
with aphasia to evaluate cognitive function. The FMA andWolf Motor Function Test
(WMFT) were used to evaluate motor function in the affected upper limb before and after
treatment. The RCPM consists of 36 visual multiple-choice tests and does not require verbal
responses, so it is used to evaluate cognition in the aphasic patient [24]. The FMA used for
assessment of upper limb motor function includes 33 items [25], and each item is rated on a
three-point ordinal scale, with a maximum motor performance score of 66 points. The WMFT
consists of 15 functional timed tasks and the performance time of each task is measured and
summed as the total time [26].
Blood samples
Blood samples were taken between 8:30 am and 9:00 am after breakfast at 7:00 am at Tokyo
General Hospital (Tokyo, Japan). Blood samples were collected twice; before and after treat-
ment. Blood samples before treatment were collected for the purpose of analysis of the BDNF
Val66Met gene polymorphism and measurement of serum biomarkers. After 14 days of the
first blood sampling, blood samples were collected after treatment for measurement of serum
biomarkers. The obtained samples were anonymized and immediately stored at -20°C. Within
one week of collection, the stored samples were transported under freezing condition to the
laboratory of Chiba University Center for Forensic Mental Health and stored at -80°C until
subjected to analysis.
Analysis of BDNF gene polymorphism
Genomic DNA was extracted from blood samples, using the DNeasy Blood & Tissue Kit (Qia-
gen, CA). BDNF 196 A/G polymorphism was assayed, using the protocol described previously
[27,28]. Polymerase chain reaction (PCR) and the PCR-based restriction fragment length poly-
morphism (RFLP) assay were performed to genotype the DNA sequence variants of the BDNF
gene. PCR was carried out in a total volume of 25 μl with 1 unit of Ex Taq DNA polymerase
(Takara Bio, Otsu, Japan) in the reaction mixture. The primer sequences for analysis of val66-
met (196G>A) (GENBANK: AF411339; at position 95422) in exon XIIIA (position 95206–
98892) were forward: 5’-GGTGAGAAGAGTGATGACCA-3’ (position 95214–95233) and
reverse: 5’-GCCAGCCAATTCTCTTTTTG-3’ (position 95892–95911). The former contains
the first met and the second thr (MT), while the latter contains 223lys, 224lys, 225arg, 226ile,
227gly and 228trp (KKRIGW). The amplification conditions were initiated at 94°C for 4 min,
followed by 32 cycles consisting of denaturation at 94°C for 30 sec, annealing at 58°C for 30 sec
and extension at 72°C for 30 sec, with a final extension step of 7 min at 72°C. The PCR
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products were digested at 37°C with restriction enzyme PmaCI (Takara Shuzo, Kyoto, Japan)
for analysis of 196G>A (val66met) in exon XIIIA, followed by 2% agarose gel- electrophoresis
with ethidium bromide staining.
Measurement of serum levels of proBDNF, BDNF and MMP-9
Serum levels of proBDNF, mature BDNF, and MMP-9 were measured using the human
proBDNF Rapid ELISA Kit (Biosensis, Thebarton, SA, Australia), the human BDNF ELISA Kit
(Aviscera Bioscience, Santa Clara, CA), and the human MMP-9 ELISA Kit (R&D Systems,
Minneapolis, MN), respectively. To minimize assay variance, serum levels of proBDNF, mature
BDNF, and MMP-9 were measured in each subject in a single day. All measurements were per-
formed in duplicates and the protocols were performed according to the instructions provided
by the manufacturers. The optical density of each well was measured using an automated
microplate reader (Emax; Molecular Devices, Sunnyvale, CA).
Statistical analysis
All statistical analyses were performed using SPSS version 21.0 (IBM, Somers, NY). The Stu-
dent’s t-test was used for comparison of normally distributed parameters and the Mann-Whit-
ney test was used for comparison of parameters that showed skewed distribution pattern. The
chi-squared test was used for comparison of categorical data. Data were analyzed using two-
way analysis of variance (ANOVA). Correlations between clinical variables and serum bio-
markers were carried out using Spearman’s correlation. Data of WMFT, proBDNF, and MMP-
9, which showed skewed distribution patterns, were log-transformed to allow meaningful sta-
tistical analysis. A P value of less than 0.05 was considered to denote statistical significance.
Results
The rTMS plus rehabilitation group included 62 patients, while rehabilitation without rTMS
group included 33 patients. The baseline clinical characteristics of all patients are summarized
in Table 1. There were no differences in the clinical features of patients of the two groups.
Table 1. Comparison of clinical characteristics at baseline.
Rehabilitation with rTMS group (n = 62) Rehabilitation without rTMS group (n = 33) p value
Age (years), mean±SD 62.3±11.0 66.2±10.8 0.097
Female, n (%) 21 (33.9) 16 (48.5) 0.189
Subtype of stroke 0.174
Hemorrhage, n (%) 34 (54.8) 14 (42.4)
Infarction, n (%) 28 (45.2) 19 (57.6)
Stroke lesion 0.392
Cortical, n (%) 8 (12.9) 6 (18.2)
Subcortical, n (%) 49 (79.0) 22 (66.7)
Brain stem, n (%) 5 (8.1) 5 (15.2)
FMA, mean±SD 50.2±12.4 52.9±12.7 0.307
WMFT log performance time, mean±SD 2.02±1.45 1.70±1.29 0.303
MMSE, median [IQR] 29.0, [28.0–30.0] 29.0, [27.0–30.0] 0.616
SD: Standard Deviation; FMA: Fugl-Meyer Assessment; WMFT: Wolf Motor Function Test; MMSE: Mini-Mental State Examination; IQR: Interquartile
range.
doi:10.1371/journal.pone.0152241.t001
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Improvement of motor function in affected upper limb after 2-week rTMS
None of the patients who received rTMS treatment showed any adverse effects. Two-way
repeated measures ANOVA of FMA data showed a significant time effect (group: F = 0.5,
df = 1,93, p = 0.476, time: F = 87.6, df = 1,93, p<0.001) and a significant group-by-time interac-
tion (F = 7.4, df = 1,93, p = 0.008) (Fig 1A). The results showed that the increase in FMA was
significantly higher in the rTMS plus rehabilitation group than the rehabilitation only group.
Two-way repeated measures ANOVA of WMFT log performance time showed a significant
time effect (group: F = 0.4, df = 1,93, p = 0.507, time: F = 39.7, df = 1,93, p<0.001) and a signifi-
cant group-by-time interaction (F = 4.6, df = 1,93, p = 0.035) (Fig 1B). The results showed that
the decrease in WMFT log performance time was significantly higher in the rTMS plus rehabil-
itation group than the rehabilitation only group.
Effect of treatment on serum BDNF, proBDNF and MMP-9 levels
Serum proBDNF levels were compared before and after treatment in 50 patients of the rTMS
plus rehabilitation group and 26 patients before and 22 patients of the rehabilitation only
group since serum levels of proBDNF in the other patients were below the minimum detectable
concentration of the kit. Two-way repeated measures ANOVA of BDNF data showed a signifi-
cant group-by-time interaction (group: F = 2.1, df = 1,93, p = 0.152, time: F = 1.7, df = 1,93,
p = 0.193, interaction (group x time): F = 4.1, df = 1,93, p = 0.047) (Fig 2A). There were no sig-
nificant effects and interaction in serum proBDNF levels (group: F = 0.2, df = 1,66, p = 0.685,
time: F = 0.1, df = 1,66, p = 0.730, interaction (group x time): F = 2.6, df = 1,66, p = 0.110) (Fig
2B). Furthermore, two-way repeated measures ANOVA of the ratio of BDNF to total BDNF
(BDNF plus proBDNF) showed a significant group-by-time interaction (group: F = 0.3,
df = 1,66, p = 0.580, time: F = 2.6, df = 1,66, p = 0.109, interaction (group x time): F = 6.4,
df = 1,66, p = 0.014) (Fig 2C).
Two-way repeated measures ANOVA of MMP-9 data showed a significant group-by-time
interaction (group: F = 1.5, df = 1,93, p = 0.220, time: F = 3.9, df = 1,93, p = 0.053, interaction
(group x time): F = 7.0, df = 1,93, p = 0.010) (Fig 2D).
Fig 1. Effect of rehabilitation with and without 2-week rTMS on FMA andWMFT log performance time. (A) FMA: There was a significant interaction
between group and time (F = 7.4, df = 1,93, p = 0.008). (B) WMFT log performance time: There was a significant interaction between group and time (F = 4.6,
df = 1,93, p = 0.035).
doi:10.1371/journal.pone.0152241.g001
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Correlations with clinical evaluation of upper limb motor function
Baseline BDNF and MMP-9 serum levels did not correlate with changes in FMA andWMFT
log performance time in both treatment groups. Furthermore, proBDNF serum levels did not
correlate with the increase in FMA score in both groups. Interestingly, there was a significant
negative (ρ = -0.422, p = 0.002) correlation between proBDNF serum levels and decrease in
WMFT log performance time in the rTMS plus rehabilitation group (n = 50), but not in the
rehabilitation group (n = 26) (Fig 3).
Effect of BDNF Val66Met polymorphism on improvement in motor
function
Based on the small number of patients with met allele, we divided the patients into two groups
(val66val vs. val66met and met66met). Two-way repeated measures ANOVA of FMA data
showed statistical significance in the rTMS plus rehabilitation group (gene: F = 0.05, df = 1,60,
p = 0.828, time: F = 87.0, df = 1,60, p<0.001, interaction (gene x time): F = 1.0, df = 1,60,
p = 0.333) (Fig 4A), as well as in the rehabilitation group (gene: F = 4.8, df = 1,31, p = 0.036,
Fig 2. Effects of rehabilitation with and without 2-week rTMS on serum levels of biomarkers. (A) Mature BDNF: There was a significant interaction
between group and time (F = 4.1, df = 1,93, p = 0.047). (B) ProBDNF: There was no significant interaction between group and time (F = 2.6, df = 1,65,
p = 0.110). (C) BDNF/total BDNF (BDNF and proBDNF) ratio: There was a significant interaction between group and time (F = 6.4, df = 1,66, p = 0.014). (D)
MMP-9: There was a significant interaction between group and time (F = 7.0, df = 1,93, p = 0.010).
doi:10.1371/journal.pone.0152241.g002
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time: F = 21.0, df = 1,31, p<0.001, interaction (gene x time): F = 0.4, df = 1,31, p = 0.513)
(Fig 4B).
Two-way repeated measures ANOVA of WMFT log performance time data showed statisti-
cal significance in the rTMS plus rehabilitation group (gene: F = 0.1, df = 1,60, p = 0.740, time:
F = 45.3, df = 1,60, p<0.001, interaction (gene x time): F = 2.7, df = 1,60, p = 0.108) (Fig 4C), as
well as in the rehabilitation monotherapy group (gene: F = 2.5, df = 1,31, p = 0.127, time:
F = 7.2, df = 1,31, p = 0.012, interaction (gene x time): F = 0.1, df = 1,31, p = 0.798) (Fig 4D).
Discussion
This is the first report to show that 2-week low-frequency rTMS increases serum levels of
mature BDNF and MMP-9 in stroke patients. Given the key role of BDNF-TrkB signaling in
neuroplasticity, it is likely that high serum levels of mature BDNF play at least some role in the
beneficial actions of rTMS on motor function in the affected upper limb.
Accumulating evidence suggests that rTMS is effective treatment for poststroke hemiparesis
[1]. Rehabilitation with low-frequency rTMS resulted in greater improvement of upper limb
hemiparesis than rehabilitation without rTMS. In the present study, the rTMS plus rehabilita-
tion group showed better improvement in FMA andWMFT than the rehabilitation alone
group, as reported previously by Abo et al. [29].
Fig 3. Correlation between baseline serum proBDNF levels and decrease in WMFT log performance time. There was a significant correlation between
serum proBDNF levels and decrease in WMFT log performance time in patients treated with rehabilitation and rTMS (n = 50, ρ = -0.422, p = 0.002) but not in
those treated with rehabilitation only.
doi:10.1371/journal.pone.0152241.g003
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The rTMS treatment is reported to result in significant increases in serum levels of total
BDNF (mature BDNF + proBDNF) in patients with depression [11]. However, another study
showed no such changes in serum levels of total BDNF after rTMS combined with rehabilitation
[30]. In the above two studies, the BDNF ELISA kit did not recognize BDNF (mature form) and
proBDNF [15]. One possibility for the discrepancy between the studies is the use of ELISA kit.
In the present study, we found that serum levels of mature BDNF increased after 2-week rTMS
plus rehabilitation, but decreased after 2-week rehabilitation only. Furthermore, serum levels of
MMP-9 increased after 2-week rTMS plus rehabilitation whereas they decreased after 2-week
rehabilitation only. Considering the role of MMP-9 in the conversion of proBDNF to mature
BDNF, it is interesting to note the high levels of serummature BDNF after 2-week rTMS.
Accumulating evidence indicates that both proBDNF and mature BDNF play important
roles in various physiological functions, eliciting opposite effects via the p75NTR and TrkB
receptors, respectively [7,8,14]. These two parameters have not so far been measured accurately
due to the limited specificity of the BDNF antibody. Luckily, the newly available ELISA Kit
allowed us to measure separately the levels of both BDNF (mature form) and proBDNF [15].
Fig 4. Effects of BDNF Val66Met gene polymorphism on FMA andWMFT log performance time. Effects of BDNF Val66Met gene polymorphism on (A)
FMA and (B) WMFT log performance time in patients who received rehabilitation plus rTMS combination therapy. Effects of rehabilitation monotherapy on
FMA (C) andWMFT log performance time (D) in Val66Val and Val66Met patients.
doi:10.1371/journal.pone.0152241.g004
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Our results showed that rTMS plus rehabilitation slightly reduced proBDNF serum levels,
whereas rehabilitation alone resulted in a slight increase in proBDNF serum levels. Based on
the above changes, rehabilitation alone resulted in reduction in the ratio of mature BDNF/total
BDNF, whereas it increased slightly in patients of the rTMS plus rehabilitation group. These
findings suggest that low-frequency rTMS can activate the conversion of proBDNF to mature
BDNF, and that such change enhances the effects of rehabilitation therapy on improvement of
upper limb hemiparesis.
The results also showed a negative correlation between baseline serum proBDNF and
improvement in WMFT, reflecting improvement in upper limb motor function. This prelimi-
nary result suggests that high baseline level of serum proBDNF could be used to predict poor
improvement of motor function in the affected upper limbs, or alternatively, used as a bio-
marker of the response to rehabilitation in poststroke patients with hemiparesis. Further stud-
ies of large samples are needed to confirm these conclusions.
Several studies have reported that BDNF gene val66met polymorphism has a negative effect
on the outcome of rTMS therapy [13,31]. However, the present results indicate that the out-
come of rTMS therapy is not altered by this polymorphism, although we acknowledge the
small number of patients included in the study. Nonetheless, our results demonstrate that
rTMS combined with rehabilitation improves motor function in the affected limb after stroke
irrespective of BDNF gene polymorphism. Whereas we did not determine the reason for the
above differences between the two studies, we believe it relates to differences in the methodol-
ogy; the rTMS sessions applied in the present study outnumbered those used in the previous
study [13].
Limitations
The present study has several limitations. First, it was not a randomized controlled trial, and
rTMS treatment was directly applied to the patient. In addition, the sample size was too small
to allow firm conclusions. Further randomized controlled studies of larger population are
needed. Second, the sensitivity of the human proBDNF ELISA kits used in this study is less
than ideal; in fact, serum levels of proBDNF in some patients were not detected, whereas they
were detected in all subjects who participated in a Swedish study [32] and Israeli study [33],
suggesting ethnic differences in serum proBDNF levels. The development of highly sensitive
proBDNF ELISA kits is desirable for accurate measurement of proBDNF serum levels.
Conclusions
Two-week low-frequency rTMS plus rehabilitation therapy resulted in greater improvement of
upper limb motor function than rehabilitation alone, and this effect was mediated, at least in
part, through rises in serum levels of mature BDNF and MMP-9 in poststroke patients. Mature
BDNF, proBDNF, and MMP-9 could be potentially useful biomarkers of the response to ther-
apy in poststroke patients with upper limb motor deficit.
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